Related coverage linked through entity extraction aliases.
Jun 25, 2026
Novartis has announced three separate partnership deals worth over $5 billion combined with Antares Therapeutics, Orionis Biosciences, and Unnatural Products. The agreements target undruggable cancers, molecular glue drugs, and cardiovascular therapies respectively using each partner's proprietary platforms.
Apr 14, 2026
Sana Biotechnology named Brian Piper executive vice president and CFO as it advanced SC451 and SG293. The company reported a fourth-quarter loss of $59 million and cash of $138 million.
Feb 17, 2026
Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer on February 17, 2026. Piper brings over 25 years of biopharmaceutical financial expertise to the cell and gene therapy company.
